Global Ciprofibrate 麻豆原创 Research Report 2024

Publication ID:

PB508244909

Publication Date:

August 7, 2024

Pages:

111

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The ciprofibrate is a phenoxyacetic acid hypolipidemic drug, which belongs to a new type of fibric acid hypolipidemic drug.
The global Ciprofibrate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The ciprofibrate can be used alone or in combination with other drugs, and has a strong blood lipid-lowering effect, good oral absorption, and few side effects.
This report aims to provide a comprehensive presentation of the global market for Ciprofibrate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ciprofibrate.
Report Scope
The Ciprofibrate market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Ciprofibrate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ciprofibrate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Ark Pharm
Pure Chemistry Scientific
LGM Pharma
Syntechem
TOKYO CHEMICAL INDUSTRY
TCI AMERICA
MedChemexpress LLC
AdooQ BioScience
Cato Research Chemicals
AN PharmaTech
TargetMol Chemicals Inc
Alfa Chemistry
InvivoChem
Zhejiang Nisikang Pharmaceutical
Zhejiang Hengkang Pharmaceutical
HUANGSHI FUERTAI
Jinan Xuanzheng Pharmaceutical
Beijing Bailingwei Technology
Shanghai Merrill Biochemical Technology
Shanghai Baishikai Chemical Technology
Shanghai Demo Pharmaceutical Technology
Shanghai Jingyan Chemical Technology
Kaishi (Shanghai) Technology
Shanghai Lanke Pharmaceutical Technology
Wuhan Fuxin Chemical
Shenzhen Faith Biotechnology
Segment by Type
Solid Particle
Capsule
Segment by Application
Type II/IV Hyperlipoproteinemia
Endogenous High Cholesterol
Hypertriglyceridemia
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ciprofibrate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ciprofibrate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Ciprofibrate 麻豆原创 Overview
1.1 Product Overview and Scope of Ciprofibrate
1.2 Ciprofibrate Segment by Type
1.2.1 Global Ciprofibrate 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Solid Particle
1.2.3 Capsule
1.3 Ciprofibrate Segment by Application
1.3.1 Global Ciprofibrate 麻豆原创 Value by Application: (2024-2030)
1.3.2 Type II/IV Hyperlipoproteinemia
1.3.3 Endogenous High Cholesterol
1.3.4 Hypertriglyceridemia
1.3.5 Others
1.4 Global Ciprofibrate 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Ciprofibrate Revenue 2019-2030
1.4.2 Global Ciprofibrate Sales 2019-2030
1.4.3 Global Ciprofibrate 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Ciprofibrate 麻豆原创 Competition by Manufacturers
2.1 Global Ciprofibrate Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Ciprofibrate Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Ciprofibrate Average Price by Manufacturers (2019-2024)
2.4 Global Ciprofibrate Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Ciprofibrate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Ciprofibrate, Product Type & Application
2.7 Ciprofibrate 麻豆原创 Competitive Situation and Trends
2.7.1 Ciprofibrate 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Ciprofibrate Players 麻豆原创 Share by Revenue
2.7.3 Global Ciprofibrate 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Ciprofibrate Retrospective 麻豆原创 Scenario by Region
3.1 Global Ciprofibrate 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Ciprofibrate Global Ciprofibrate Sales by Region: 2019-2030
3.2.1 Global Ciprofibrate Sales by Region: 2019-2024
3.2.2 Global Ciprofibrate Sales by Region: 2025-2030
3.3 Global Ciprofibrate Global Ciprofibrate Revenue by Region: 2019-2030
3.3.1 Global Ciprofibrate Revenue by Region: 2019-2024
3.3.2 Global Ciprofibrate Revenue by Region: 2025-2030
3.4 North America Ciprofibrate 麻豆原创 Facts & Figures by Country
3.4.1 North America Ciprofibrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Ciprofibrate Sales by Country (2019-2030)
3.4.3 North America Ciprofibrate Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Ciprofibrate 麻豆原创 Facts & Figures by Country
3.5.1 Europe Ciprofibrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Ciprofibrate Sales by Country (2019-2030)
3.5.3 Europe Ciprofibrate Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Ciprofibrate 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Ciprofibrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Ciprofibrate Sales by Country (2019-2030)
3.6.3 Asia Pacific Ciprofibrate Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Ciprofibrate 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Ciprofibrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Ciprofibrate Sales by Country (2019-2030)
3.7.3 Latin America Ciprofibrate Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Ciprofibrate 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Ciprofibrate 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Ciprofibrate Sales by Country (2019-2030)
3.8.3 Middle East and Africa Ciprofibrate Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Ciprofibrate Sales by Type (2019-2030)
4.1.1 Global Ciprofibrate Sales by Type (2019-2024)
4.1.2 Global Ciprofibrate Sales by Type (2025-2030)
4.1.3 Global Ciprofibrate Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Ciprofibrate Revenue by Type (2019-2030)
4.2.1 Global Ciprofibrate Revenue by Type (2019-2024)
4.2.2 Global Ciprofibrate Revenue by Type (2025-2030)
4.2.3 Global Ciprofibrate Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Ciprofibrate Price by Type (2019-2030)
5 Segment by Application
5.1 Global Ciprofibrate Sales by Application (2019-2030)
5.1.1 Global Ciprofibrate Sales by Application (2019-2024)
5.1.2 Global Ciprofibrate Sales by Application (2025-2030)
5.1.3 Global Ciprofibrate Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Ciprofibrate Revenue by Application (2019-2030)
5.2.1 Global Ciprofibrate Revenue by Application (2019-2024)
5.2.2 Global Ciprofibrate Revenue by Application (2025-2030)
5.2.3 Global Ciprofibrate Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Ciprofibrate Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Ark Pharm
6.1.1 Ark Pharm Corporation Information
6.1.2 Ark Pharm Description and Business Overview
6.1.3 Ark Pharm Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Ark Pharm Ciprofibrate Product Portfolio
6.1.5 Ark Pharm Recent Developments/Updates
6.2 Pure Chemistry Scientific
6.2.1 Pure Chemistry Scientific Corporation Information
6.2.2 Pure Chemistry Scientific Description and Business Overview
6.2.3 Pure Chemistry Scientific Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pure Chemistry Scientific Ciprofibrate Product Portfolio
6.2.5 Pure Chemistry Scientific Recent Developments/Updates
6.3 LGM Pharma
6.3.1 LGM Pharma Corporation Information
6.3.2 LGM Pharma Description and Business Overview
6.3.3 LGM Pharma Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.3.4 LGM Pharma Ciprofibrate Product Portfolio
6.3.5 LGM Pharma Recent Developments/Updates
6.4 Syntechem
6.4.1 Syntechem Corporation Information
6.4.2 Syntechem Description and Business Overview
6.4.3 Syntechem Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Syntechem Ciprofibrate Product Portfolio
6.4.5 Syntechem Recent Developments/Updates
6.5 TOKYO CHEMICAL INDUSTRY
6.5.1 TOKYO CHEMICAL INDUSTRY Corporation Information
6.5.2 TOKYO CHEMICAL INDUSTRY Description and Business Overview
6.5.3 TOKYO CHEMICAL INDUSTRY Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.5.4 TOKYO CHEMICAL INDUSTRY Ciprofibrate Product Portfolio
6.5.5 TOKYO CHEMICAL INDUSTRY Recent Developments/Updates
6.6 TCI AMERICA
6.6.1 TCI AMERICA Corporation Information
6.6.2 TCI AMERICA Description and Business Overview
6.6.3 TCI AMERICA Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.6.4 TCI AMERICA Ciprofibrate Product Portfolio
6.6.5 TCI AMERICA Recent Developments/Updates
6.7 MedChemexpress LLC
6.6.1 MedChemexpress LLC Corporation Information
6.6.2 MedChemexpress LLC Description and Business Overview
6.6.3 MedChemexpress LLC Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 MedChemexpress LLC Ciprofibrate Product Portfolio
6.7.5 MedChemexpress LLC Recent Developments/Updates
6.8 AdooQ BioScience
6.8.1 AdooQ BioScience Corporation Information
6.8.2 AdooQ BioScience Description and Business Overview
6.8.3 AdooQ BioScience Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AdooQ BioScience Ciprofibrate Product Portfolio
6.8.5 AdooQ BioScience Recent Developments/Updates
6.9 Cato Research Chemicals
6.9.1 Cato Research Chemicals Corporation Information
6.9.2 Cato Research Chemicals Description and Business Overview
6.9.3 Cato Research Chemicals Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Cato Research Chemicals Ciprofibrate Product Portfolio
6.9.5 Cato Research Chemicals Recent Developments/Updates
6.10 AN PharmaTech
6.10.1 AN PharmaTech Corporation Information
6.10.2 AN PharmaTech Description and Business Overview
6.10.3 AN PharmaTech Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.10.4 AN PharmaTech Ciprofibrate Product Portfolio
6.10.5 AN PharmaTech Recent Developments/Updates
6.11 TargetMol Chemicals Inc
6.11.1 TargetMol Chemicals Inc Corporation Information
6.11.2 TargetMol Chemicals Inc Ciprofibrate Description and Business Overview
6.11.3 TargetMol Chemicals Inc Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.11.4 TargetMol Chemicals Inc Ciprofibrate Product Portfolio
6.11.5 TargetMol Chemicals Inc Recent Developments/Updates
6.12 Alfa Chemistry
6.12.1 Alfa Chemistry Corporation Information
6.12.2 Alfa Chemistry Ciprofibrate Description and Business Overview
6.12.3 Alfa Chemistry Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Alfa Chemistry Ciprofibrate Product Portfolio
6.12.5 Alfa Chemistry Recent Developments/Updates
6.13 InvivoChem
6.13.1 InvivoChem Corporation Information
6.13.2 InvivoChem Ciprofibrate Description and Business Overview
6.13.3 InvivoChem Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.13.4 InvivoChem Ciprofibrate Product Portfolio
6.13.5 InvivoChem Recent Developments/Updates
6.14 Zhejiang Nisikang Pharmaceutical
6.14.1 Zhejiang Nisikang Pharmaceutical Corporation Information
6.14.2 Zhejiang Nisikang Pharmaceutical Ciprofibrate Description and Business Overview
6.14.3 Zhejiang Nisikang Pharmaceutical Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Zhejiang Nisikang Pharmaceutical Ciprofibrate Product Portfolio
6.14.5 Zhejiang Nisikang Pharmaceutical Recent Developments/Updates
6.15 Zhejiang Hengkang Pharmaceutical
6.15.1 Zhejiang Hengkang Pharmaceutical Corporation Information
6.15.2 Zhejiang Hengkang Pharmaceutical Ciprofibrate Description and Business Overview
6.15.3 Zhejiang Hengkang Pharmaceutical Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Zhejiang Hengkang Pharmaceutical Ciprofibrate Product Portfolio
6.15.5 Zhejiang Hengkang Pharmaceutical Recent Developments/Updates
6.16 HUANGSHI FUERTAI
6.16.1 HUANGSHI FUERTAI Corporation Information
6.16.2 HUANGSHI FUERTAI Ciprofibrate Description and Business Overview
6.16.3 HUANGSHI FUERTAI Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.16.4 HUANGSHI FUERTAI Ciprofibrate Product Portfolio
6.16.5 HUANGSHI FUERTAI Recent Developments/Updates
6.17 Jinan Xuanzheng Pharmaceutical
6.17.1 Jinan Xuanzheng Pharmaceutical Corporation Information
6.17.2 Jinan Xuanzheng Pharmaceutical Ciprofibrate Description and Business Overview
6.17.3 Jinan Xuanzheng Pharmaceutical Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Jinan Xuanzheng Pharmaceutical Ciprofibrate Product Portfolio
6.17.5 Jinan Xuanzheng Pharmaceutical Recent Developments/Updates
6.18 Beijing Bailingwei Technology
6.18.1 Beijing Bailingwei Technology Corporation Information
6.18.2 Beijing Bailingwei Technology Ciprofibrate Description and Business Overview
6.18.3 Beijing Bailingwei Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Beijing Bailingwei Technology Ciprofibrate Product Portfolio
6.18.5 Beijing Bailingwei Technology Recent Developments/Updates
6.19 Shanghai Merrill Biochemical Technology
6.19.1 Shanghai Merrill Biochemical Technology Corporation Information
6.19.2 Shanghai Merrill Biochemical Technology Ciprofibrate Description and Business Overview
6.19.3 Shanghai Merrill Biochemical Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Shanghai Merrill Biochemical Technology Ciprofibrate Product Portfolio
6.19.5 Shanghai Merrill Biochemical Technology Recent Developments/Updates
6.20 Shanghai Baishikai Chemical Technology
6.20.1 Shanghai Baishikai Chemical Technology Corporation Information
6.20.2 Shanghai Baishikai Chemical Technology Ciprofibrate Description and Business Overview
6.20.3 Shanghai Baishikai Chemical Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Shanghai Baishikai Chemical Technology Ciprofibrate Product Portfolio
6.20.5 Shanghai Baishikai Chemical Technology Recent Developments/Updates
6.21 Shanghai Demo Pharmaceutical Technology
6.21.1 Shanghai Demo Pharmaceutical Technology Corporation Information
6.21.2 Shanghai Demo Pharmaceutical Technology Ciprofibrate Description and Business Overview
6.21.3 Shanghai Demo Pharmaceutical Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Shanghai Demo Pharmaceutical Technology Ciprofibrate Product Portfolio
6.21.5 Shanghai Demo Pharmaceutical Technology Recent Developments/Updates
6.22 Shanghai Jingyan Chemical Technology
6.22.1 Shanghai Jingyan Chemical Technology Corporation Information
6.22.2 Shanghai Jingyan Chemical Technology Ciprofibrate Description and Business Overview
6.22.3 Shanghai Jingyan Chemical Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Shanghai Jingyan Chemical Technology Ciprofibrate Product Portfolio
6.22.5 Shanghai Jingyan Chemical Technology Recent Developments/Updates
6.23 Kaishi (Shanghai) Technology
6.23.1 Kaishi (Shanghai) Technology Corporation Information
6.23.2 Kaishi (Shanghai) Technology Ciprofibrate Description and Business Overview
6.23.3 Kaishi (Shanghai) Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Kaishi (Shanghai) Technology Ciprofibrate Product Portfolio
6.23.5 Kaishi (Shanghai) Technology Recent Developments/Updates
6.24 Shanghai Lanke Pharmaceutical Technology
6.24.1 Shanghai Lanke Pharmaceutical Technology Corporation Information
6.24.2 Shanghai Lanke Pharmaceutical Technology Ciprofibrate Description and Business Overview
6.24.3 Shanghai Lanke Pharmaceutical Technology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Shanghai Lanke Pharmaceutical Technology Ciprofibrate Product Portfolio
6.24.5 Shanghai Lanke Pharmaceutical Technology Recent Developments/Updates
6.25 Wuhan Fuxin Chemical
6.25.1 Wuhan Fuxin Chemical Corporation Information
6.25.2 Wuhan Fuxin Chemical Ciprofibrate Description and Business Overview
6.25.3 Wuhan Fuxin Chemical Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Wuhan Fuxin Chemical Ciprofibrate Product Portfolio
6.25.5 Wuhan Fuxin Chemical Recent Developments/Updates
6.26 Shenzhen Faith Biotechnology
6.26.1 Shenzhen Faith Biotechnology Corporation Information
6.26.2 Shenzhen Faith Biotechnology Ciprofibrate Description and Business Overview
6.26.3 Shenzhen Faith Biotechnology Ciprofibrate Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Shenzhen Faith Biotechnology Ciprofibrate Product Portfolio
6.26.5 Shenzhen Faith Biotechnology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Ciprofibrate Industry Chain Analysis
7.2 Ciprofibrate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Ciprofibrate Production Mode & Process
7.4 Ciprofibrate Sales and 麻豆原创ing
7.4.1 Ciprofibrate Sales Channels
7.4.2 Ciprofibrate Distributors
7.5 Ciprofibrate Customers
8 Ciprofibrate 麻豆原创 Dynamics
8.1 Ciprofibrate Industry Trends
8.2 Ciprofibrate 麻豆原创 Drivers
8.3 Ciprofibrate 麻豆原创 Challenges
8.4 Ciprofibrate 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Ark Pharm
Pure Chemistry Scientific
LGM Pharma
Syntechem
TOKYO CHEMICAL INDUSTRY
TCI AMERICA
MedChemexpress LLC
AdooQ BioScience
Cato Research Chemicals
AN PharmaTech
TargetMol Chemicals Inc
Alfa Chemistry
InvivoChem
Zhejiang Nisikang Pharmaceutical
Zhejiang Hengkang Pharmaceutical
HUANGSHI FUERTAI
Jinan Xuanzheng Pharmaceutical
Beijing Bailingwei Technology
Shanghai Merrill Biochemical Technology
Shanghai Baishikai Chemical Technology
Shanghai Demo Pharmaceutical Technology
Shanghai Jingyan Chemical Technology
Kaishi (Shanghai) Technology
Shanghai Lanke Pharmaceutical Technology
Wuhan Fuxin Chemical
Shenzhen Faith Biotechnology

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.